Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Advances in Hematology, enter your email address in the box below.

Advances in Hematology
Volume 2010, Article ID 164045, 5 pages
http://dx.doi.org/10.1155/2010/164045
Case Report

Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome

Maha A. Badawi,1 Linda M. Vickars,2 Jocelyn M. Chase,1 and Heather A. Leitch2

1Department of Medicine, St. Paul's Hospital, The University of British Columbia, Vancouver, BC, V6T1Z4, Canada
2Department of Hematology, St. Paul's Hospital, The University of British Columbia, Vancouver, BC, V6Z2A5, Canada

Received 2 November 2009; Revised 11 January 2010; Accepted 18 January 2010

Academic Editor: Elizabeta Nemeth

Copyright © 2010 Maha A. Badawi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Greenberg, C. Cox, M. M. LeBeau et al., “International scoring system for evaluating prognosis in myelodysplastic syndromes,” Blood, vol. 89, no. 6, pp. 2079–2088, 1997. View at Google Scholar
  2. C. A. Schiffer, “Clinical issues in the management of patients with myelodysplasia,” Hematology, pp. 205–210, 2006. View at Google Scholar
  3. E. Hellstrom-Lindberg, N. Gulbrandsen, G. Lindberg et al., “A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life,” British Journal of Haematology, vol. 120, no. 6, pp. 1037–1046, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Kantarjlan, J.-P. J. Issa, C. S. Rosenfeld et al., “Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study,” Cancer, vol. 106, no. 8, pp. 1794–1803, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. List, S. Kurtin, D. J. Roe et al., “Efficacy of lenalidomide in myelodysplastic syndromes,” New England Journal of Medicine, vol. 352, no. 6, pp. 549–557, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. Raza, P. Meyer, D. Dutt et al., “Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes,” Blood, vol. 98, no. 4, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. L. R. Silverman, E. P. Demakos, B. L. Peterson et al., “Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2429–2440, 2002. View at Google Scholar
  8. J. B. Porter, “Practical management of iron overload,” British Journal of Haematology, vol. 115, no. 2, pp. 239–252, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Malcovati, M. G. Della Porta, C. Pascutto et al., “Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7594–7603, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. L. Malcovati, U. Germing, A. Kuendgen et al., “Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes,” Journal of Clinical Oncology, vol. 25, no. 23, pp. 3503–3510, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. N. F. Olivieri, D. G. Nathan, J. H. Macmillan et al., “Survival in medically treated patients with homozygous β-thalassemia,” New England Journal of Medicine, vol. 331, no. 9, pp. 574–578, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. H. A. Leitch, C. S. Leger, T. A. Goodman et al., “Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy,” Clinical Leukemia, vol. 2, no. 3, pp. 205–211, 2008. View at Google Scholar
  13. N. Gattermann, “Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload,” International Journal of Hematology, vol. 88, no. 1, pp. 24–29, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. M. Bennett, “Consensus statement on iron overload in myelodysplastic syndromes,” American Journal of Hematology, vol. 83, no. 11, pp. 858–861, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. M. Bennett, D. Catovsky, M. T. Daniel et al., “Proposals for the classification of the myelodysplastic syndromes,” British Journal of Haematology, vol. 51, no. 2, pp. 189–199, 1982. View at Google Scholar
  16. J. W. Vardiman, N. L. Harris, and R. D. Brunning, “The World Health Organization (WHO) classification of the myeloid neoplasms,” Blood, vol. 100, no. 7, pp. 2292–2302, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. Del Río Garma, L. C. Fernandez, and B. F. J. Fonrodona, “Desferrioxamine in the treatment of myelodysplastic syndromes,” Haematologica, vol. 82, no. 5, pp. 639–640, 1997. View at Google Scholar
  18. P. D. Jensen, L. Heickendorff, B. Pedersen et al., “The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload,” British Journal of Haematology, vol. 94, no. 2, pp. 288–299, 1996. View at Google Scholar · View at Scopus
  19. E. Messa, D. Cilloni, F. Messa, F. Arruga, A. Roetto, and G. Saglio, “Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis,” Acta Haematologica, vol. 120, no. 2, pp. 70–74, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. P. D. Jensen, I. M. Jensen, and J. Ellegaard, “Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome,” British Journal of Haematology, vol. 80, no. 1, pp. 121–124, 1992. View at Google Scholar · View at Scopus
  21. E. Angelucci, B. Turlin, D. Canatan et al., “Iron chelation therapy with deferasirox (Exjade, ICL670) or deferoxaimine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis,” Blood, vol. 106, no. 11, p. 757a, 2005. View at Google Scholar
  22. G. M. Brittenham, P. M. Griffith, A. W. Nienhuis et al., “Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major,” New England Journal of Medicine, vol. 331, no. 9, pp. 567–573, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. B. A. Davis and J. B. Porter, “Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia,” Blood, vol. 95, no. 4, pp. 1229–1236, 2000. View at Google Scholar · View at Scopus
  24. N. F. Olivieri and G. M. Brittenham, “Iron-chelating therapy and the treatment of thalassemia,” Blood, vol. 89, no. 3, pp. 739–761, 1997. View at Google Scholar
  25. C. Rose, S. Brechignac, D. Vassilief et al., “Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM,” Blood, vol. 110, no. 11, pp. 80–81a, 2007. View at Google Scholar
  26. J. H. Marsh, M. Hundert, and P. Schulman, “Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia,” British Journal of Haematology, vol. 76, no. 1, pp. 148–149, 1990. View at Google Scholar · View at Scopus
  27. W. Breuer, M. Shvartsman, and Z. I. Cabantchik, “Intracellular labile iron,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 3, pp. 350–354, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. R. S. Britton, K. L. Leicester, and B. R. Bacon, “Iron toxicity and chelation therapy,” International Journal of Hematology, vol. 76, no. 3, pp. 219–228, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. M. E. Smeets, G. Vreugdenhil, and R. S. Holdrinet, “Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis,” American Journal of Hematology, vol. 51, no. 3, pp. 243–244, 1996. View at Google Scholar
  30. A. A. Di Tucci, R. Murru, D. Alberti, B. Rabault, S. Deplano, and E. Angelucci, “Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670),” European Journal of Haematology, vol. 78, no. 6, pp. 540–542, 2007. View at Publisher · View at Google Scholar · View at PubMed
  31. S.-J. Park and C.-W. Han, “Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis,” Journal of Korean Medical Science, vol. 23, no. 2, pp. 320–323, 2008. View at Publisher · View at Google Scholar · View at PubMed
  32. J. Hartmann, U. Sinzig, G. Wulf et al., “Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS,” Blood, vol. 11, p. 932a, 2008. View at Google Scholar
  33. L. J. Anderson, M. A. Westwood, S. Holden et al., “Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2∗ cardiovascular magnetic resonance,” British Journal of Haematology, vol. 127, no. 3, pp. 348–355, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. G. J. Anderson, “Mechanisms of iron loading and toxicity,” American Journal of Hematology, vol. 82, no. 12, supplement, pp. 1128–1131, 2007. View at Publisher · View at Google Scholar · View at PubMed
  35. J. Amer and E. Fibach, “Oxidative status of platelets in normal and thalassemic blood,” Thrombosis and Haemostasis, vol. 92, no. 5, pp. 1052–1059, 2004. View at Publisher · View at Google Scholar
  36. J. Amer, A. Goldfarb, and E. Fibach, “Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells,” Cytometry A, vol. 60, no. 1, pp. 73–80, 2004. View at Google Scholar
  37. B. P. Esposito, W. Breuer, P. Sirankapracha, P. Pootrakul, C. Hershko, and Z. I. Cabantchik, “Labile plasma iron in iron overload: redox activity and susceptibility to chelation,” Blood, vol. 102, no. 7, pp. 2670–2677, 2003. View at Publisher · View at Google Scholar · View at PubMed
  38. E. Rachmilewitz, D. Merkel, H. Ghoti et al., “Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox,” Blood, vol. 112, no. 11, pp. A924–A925, 2008. View at Google Scholar
  39. L. S. A. Chan, R. Buckstein, M. D. Reis et al., “Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML?” Blood, vol. 112, no. 11, p. 928a, 2008. View at Google Scholar
  40. N. Szuber, J. L. Buss, S. Soe-Lin et al., “Alternative treatment paradigm for thalassemia using iron chelators,” Experimental Hematology, vol. 36, no. 7, pp. 773–785, 2008. View at Google Scholar
  41. A. F. List, M. R. Baer, D. Steensma et al., “Deferasirox (ICL670); Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS),” Blood, vol. 112, no. 11, p. 523a, 2008. View at Google Scholar
  42. X. Ren, K. L. Dorrington, P. H. Maxwell, and P. A. Robbins, “Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans,” Journal of Applied Physiology, vol. 89, no. 2, pp. 680–686, 2000. View at Google Scholar
  43. E. Messa, I. Defilippi, A. Roetto et al., “Deferasirox is the only iron chelator acting as a potent NFKB inhibitor in myelodysplastic syndromes,” Blood, vol. 112, no. 11, p. 923a, 2008. View at Google Scholar
  44. E. M. Sloand, L. Mainwaring, M. Fuhrer et al., “Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome,” Blood, vol. 106, no. 3, pp. 841–851, 2005. View at Publisher · View at Google Scholar · View at PubMed